Koszorúér-betegség: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• PCSK9 14
• SGLT2 12
• APOE 0
• GLP-1 4
• NLRP3 2
• PPAR 0
• IL-6 2
• NRF2 0
• CD40 0
• AKT 0
• VEGF 0
• TNF 1
• PI3K 0
• SIRT1 0
• TLR4 0
• TP53 0
• HMGB1 0
• STAT3 0
• HIF-1 0
• AMPK 0
• IL-1 1
• JAK 0
• MMP-9 0
• STING 1
• ACE2 0
• ERK 0
• GIP 1
• mTOR 0
• PD-1 0
• BDNF 0
• COX-2 0
• CXCR4 1
• DPP-4 0
• FGFR 0
• HER2 0
• IL-17 1
• MAPK 0
• PTEN 0
• TREM2 0
• YAP 0
• ABL1 0
• ALK 0
• ANGPTL3 0
• APP 0
• BACE1 0
• BCL-2 0
• BRAF 0
• BTK 0
• CCR5 0
• CGRP 0
• CTLA-4 0
• CTNNB1 0
• EZH2 0
• FOXP3 0
• FTO 0
• G6PD 0
• GPX4 0
• HSP90 0
• IL-4 1
• LRRK2 0

12+ intézményből 12, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• U.S. Department of Veterans Affairs · IK1

  Evaluating hypertension care delivery in Veterans with rheumatoid arthritis to improve cardiovascular disease prevention

  Durham Va Medical Center· Durham, Egyesült Államok· until 2028. okt.

• U.S. Department of Veterans Affairs · IK6

  ISRM Research Career Scientist Award Application

  Veterans Health Administration· Pittsburgh, Egyesült Államok· until 2031. szept.

• U.S. Department of Veterans Affairs · I01

  Nitrated oleic acid-mediated angiogenesis and long-term functional recovery after ischemic stroke

  Veterans Health Administration· Pittsburgh, Egyesült Államok· until 2030. szept.

• NIH NINR · R01

  Discovery of Symptom Burdens and Their Associations with Health Outcomes among People Living with HIV

  University of Texas Hlth Sci Ctr Houston· Houston, Egyesült Államok· 402 355 USD awarded in fiscal year 2026· until 2030. jún.

• NIH NLM · R21

  MACE-Alert: An Artificial Intelligence based Assessment and Triage of Undifferentiated Chest Pain

  University of California, San Diego· La Jolla, Egyesült Államok· 216 000 USD awarded in fiscal year 2026· until 2028. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unmasking the Perivascular Adipose Tissue's Role in Diabetic Vascular Disease From Molecular Clues to Clinical Impact (IMAPERFAT)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 236 340 EUR· until 2029. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Delineating and eradicating cardiovascular inflammageing (DEFLAME)

  Technische Universiteit Eindhoven· Eindhoven, Hollandia· EU contribution 2 500 000 EUR· until 2032. febr.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Predicting Female-Predominant Cardiovascular Dissections via multi-scale Hormonal, Imaging, and Biomechanical Integration (DISSEX)

  Aarhus Universitet· Aarhus C, Dánia· EU contribution 1 499 585 EUR· until 2032. febr.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  DEVELOPMENT OF A NANOHYBRID SYSTEM BASED WEARABLE MICROFLUIDIC PHOTOELECTROCHEMICAL SENSOR FOR THE ON-DEMAND cTnI DETECTION (NANOPEC)

  Kauno Technologijos Universitetas· Kaunas, Litvánia· EU contribution 196 976 EUR· until 2029. jan.· 3 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Socio-Environmental Determinants of Health in Small States (SEEDS)

  Universita Ta Malta· Msida, Málta· EU contribution 205 314 EUR· until 2029. jan.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 1988 running projects, newest first. Listed amounts together: 1,2 Mrd USD + 236,0 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCI

  NCT05613426· Henan Institute of Cardiovascular Epidemiology· Frissítve: 2026. máj. 22.

  “Slow patient enrollment and lack of financial support”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Immunomodulatory Effects of PCSK9 Inhibition

  NCT05720156· Massachusetts General Hospital· Frissítve: 2025. szept. 26.

  “Lack of Feasibility”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

  NCT05739383· Novartis Pharmaceuticals· Forrás

• Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

  NCT05360446· Novartis Pharmaceuticals· Forrás

• A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma

  NCT07803679· Amgen· Forrás

• Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia

  NCT05192941· Novartis Pharmaceuticals· Forrás

• Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography

  NCT06863545· Second Affiliated Hospital, Zhejiang University, School of Medicine· Forrás

• PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in Acute Coronary Syndromes (REPRESS)

  NCT06791031· West China Hospital· Forrás

• Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study

  NCT07084259· Hanyang University Seoul Hospital· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 14
• Organoids 1
• Mendelian Randomization Analysis 136
• CRISPR-Cas Systems 4
• Gene Expression Profiling 48
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 1
• Exome Sequencing 6
• Proteomics 68
• Metabolomics 41
• Mass Spectrometry 5
• Flow Cytometry 26
• Immunohistochemistry 12
• Positron-Emission Tomography 64
• Magnetic Resonance Imaging 66
• Machine Learning 163
• Deep Learning 85
• Cohort Studies 405
• Genome-Wide Association Study 163

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.